Adaptive Biotechnologies Corporation
ADPT
Kedudukan dalam Saham
#4106
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Harga Saham
$24.75
Modal Pasaran
$3.95B
Perubahan (1 hari)
3.32%
Perubahan (1 tahun)
38.78%
Negara
US
Perdagangan Adaptive Biotechnologies Corporation (ADPT)
Kategori
Healthcare
Nisbah P/E bagi Adaptive Biotechnologies Corporation (ADPT)
Nisbah P/E pada October 2026 TTM: -62.89
Menurut laporan kewangan dan harga saham terkini Adaptive Biotechnologies Corporation, nisbah P/E semasa (TTM) ialah -62.89. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak -5.53.
Sejarah nisbah P/E bagi Adaptive Biotechnologies Corporation dari 2017 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | -62.89 | 51.86% |
| 2025 | -41.41 | 648.33% |
| 2024 | -5.53 | 76.19% |
| 2023 | -3.14 | -58.90% |
| 2022 | -7.64 | -60.10% |
| 2021 | -19.15 | -65.53% |
| 2020 | -55.56 | -12.15% |
| 2019 | -63.25 | -30.86% |
| 2018 | -91.48 | -7.79% |
| 2017 | -99.20 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 28.78 | -145.77% |
US
|
|
| -28.36 | -54.91% |
US
|
|
| -24.57 | -60.93% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -148.23% |
NL
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.